Related Experiment Video
Updated: Jun 25, 2026
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
Treating type 2 diabetes: how safe are current therapeutic agents?
1Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University Hospital, Geneva, Switzerland. jacques.philippe@medecine.unige.ch
International Journal of Clinical Practice
|February 7, 2009
Summary
Traditional oral hypoglycaemic agents like metformin and sulphonylureas (SUs) remain valuable for type 2 diabetes (T2DM) treatment due to their proven safety. New agents require more data to establish their risk-benefit profile against established therapies.
Area of Science:
- Endocrinology
- Pharmacology
- Internal Medicine
Background:
- Type 2 diabetes mellitus (T2DM) is commonly treated with oral hypoglycaemic agents (OHAs).
- Metformin and sulphonylureas (SUs) are established first-line treatments with extensive safety data.
- Numerous novel OHAs have emerged, expanding therapeutic options.
Purpose of the Study:
- To review the established role of traditional OHAs in T2DM management.
- To highlight the emerging landscape of newer OHA classes.
- To discuss the current limitations in assessing the risk-benefit profiles of new T2DM medications.
Main Methods:
- Review of existing literature on oral hypoglycaemic agents for T2DM.
- Comparison of safety profiles and long-term data for traditional versus newer OHAs.
- Analysis of the current therapeutic decision-making process for T2DM pharmacotherapy.
Main Results:
- Metformin and SUs possess well-documented safety profiles from long-term use.
- Many newer OHAs lack extensive long-term clinical trial data and post-marketing surveillance.
- Potential serious side effects have been reported for some novel agents, complicating risk-benefit assessments.
Conclusions:
- The established safety and efficacy of metformin and SUs support their continued use in T2DM.
- Individualized treatment decisions are crucial due to limited long-term data on newer OHAs.
- Further research is needed to fully evaluate the risk-benefit ratio of newer agents compared to traditional therapies.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...